The rest of the 100 (in alphabetical order): Jan Adams, Stefan Herr, Frank Mühlenbeck, managing directors, EMBL Ventures
Jan Adams, Stefan Herr and Frank Mühlenbeck are the managing directors of EMBL Ventures, the investment arm of European Molecular Biology Laboratory.
Herr launched EMBL Ventures in 2001, having previously been a managing director of price comparison website Verivox, vice-president of venture capital firm Heidelberg Innovation and director of cooperations and licensing at communications equipment producer Hagenuk.
Adams was a postdoctoral fellow at University of Granada before joining EMBL in 2002. He focuses on drug developers and has taken on a number of board positions with portfolio companies, including inflammatory diseases therapy developer Lipid Therapeutics and autoimmune treatment developer Opsona.
Mühlenbeck came aboard EMBL Ventures in 2015 and is responsible for investments in the life sciences and medical device sectors. He was previously a partner at family office Calibrium and before that worked for tech transfer organisation Steinbeis.
EMBL Ventures has three funds under management totalling €120 ($140m) and typically leads or co-leads rounds from €5m to €40m.
